Impact of Skeletal Complications on Patients' Quality of Life, Mobility, and Functional Independence

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2008 Apr 9

PMID 18392862

Citations 91

Authors

Luis Costa

Xavier Badia

Edward Chow

Allan Lipton

Andrew Wardley

Affiliations

Soon will be listed here.

Abstract

Introduction: Skeletal-related events (SREs) from malignant bone disease cause considerable morbidity and can dramatically reduce patients' quality of life.

Discussion: Pathologic fractures often require surgical intervention and palliative radiotherapy. Thus, patients suffer impaired mobility, loss of functional independence, and diminished health-related quality of life (HRQOL). Bisphosphonates can delay the onset and reduce the incidence of SREs and have become the standard of care for the treatment of malignant bone disease; however, minimal information on the effects of bisphosphonate treatment on HRQOL is available. Targeted HRQOL assessments for patients with malignant bone disease are currently under development and are discussed herein.

Citing Articles

The role of positron emission tomography in the evaluation and management of musculoskeletal lesions-a narrative review.

Puleo J, Murtaza H, Thibodeau R, Acosta E, Cooley M, DiCaprio M Ann Jt. 2025; 10:8.

PMID: 39981426 PMC: 11840359. DOI: 10.21037/aoj-24-26.

Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Wajda B, Ferrie L, Abbott A, Elmi Assadzadeh G, Monument M, Kendal J Cancers (Basel). 2025; 17(3).

PMID: 39941757 PMC: 11816125. DOI: 10.3390/cancers17030388.

Large Italian Multicenter Study on Prognostic Value of Baselines Variables in mCRPC Patients Treated with RaCl: Ten Years of Clinical Experience.

De Feo M, Filippi L, Bauckneht M, Lodi Rizzini E, Ferrari C, Lavelli V Diagnostics (Basel). 2025; 15(3).

PMID: 39941269 PMC: 11817225. DOI: 10.3390/diagnostics15030339.

ZC3H15 suppression ameliorates bone cancer pain through inhibiting neuronal oxidative stress and microglial inflammation.

Huang L, Yan T, Wang B, Li H, Zhou N Neoplasia. 2025; 61:101123.

PMID: 39908779 PMC: 11847137. DOI: 10.1016/j.neo.2025.101123.

Risk Factors for Early Postoperative Morbidity and Mortality following Extremity Metastatic Pathologic or Impending Fracture Fixation.

Wang P, Charron B, Hali K, Raleigh M, Balso C, Macleod M Int J Surg Oncol. 2024; 2024:3565134.

PMID: 39301148 PMC: 11412750. DOI: 10.1155/2024/3565134.

References

Bang S, Park S, Kang H, Jue J, Cho I, Yun Y . Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer. 2005; 13(7):515-21. DOI: 10.1007/s00520-004-0708-0. View

Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D . Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005; 92(10):1869-76. PMC: 2361764. DOI: 10.1038/sj.bjc.6602551. View

Body J, Diel I, Bell R, Pecherstorfer M, Lichinitser M, Lazarev A . Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004; 111(3):306-312. DOI: 10.1016/j.pain.2004.07.011. View

ORourke N, McCloskey E, Houghton F, Huss H, Kanis J . Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol. 1995; 13(4):929-34. DOI: 10.1200/JCO.1995.13.4.929. View

Clemons M, Dranitsaris G, Ooi W, Cole D . A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat. 2007; 108(1):79-85. DOI: 10.1007/s10549-007-9583-y. View

Heidenreich A, Hofmann R, Engelmann U . The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol. 2000; 165(1):136-40. DOI: 10.1097/00005392-200101000-00033. View

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

Kinnane N . Burden of bone disease. Eur J Oncol Nurs. 2007; 11 Suppl 2:S28-31. DOI: 10.1016/j.ejon.2007.07.002. View

Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C . The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain. 1998; 78(3):157-169. DOI: 10.1016/S0304-3959(98)00135-3. View

10.

Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y . Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005; 23(15):3314-21. DOI: 10.1200/JCO.2005.05.116. View

11.

Ripamonti C, Fagnoni E, Campa T, Giardina V, Brunelli C, Pigni A . Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study. Support Care Cancer. 2007; 15(10):1177-84. DOI: 10.1007/s00520-007-0230-2. View

12.

Clemons M, Dranitsaris G, Ooi W, Yogendran G, Sukovic T, Wong B . Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006; 24(30):4895-900. DOI: 10.1200/JCO.2006.05.9212. View

13.

Chow E, Wu J, Hoskin P, Coia L, Bentzen S, Blitzer P . International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol. 2002; 64(3):275-80. DOI: 10.1016/s0167-8140(02)00170-6. View

14.

Hortobagyi G, Theriault R, Lipton A, Porter L, Blayney D, Sinoff C . Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16(6):2038-44. DOI: 10.1200/JCO.1998.16.6.2038. View

15.

Heidenreich A, Elert A, Hofmann R . Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. 2002; 5(3):231-5. DOI: 10.1038/sj.pcan.4500574. View

16.

Vogel C, Yanagihara R, Wood A, Schnell F, Henderson C, Kaplan B . Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004; 9(6):687-95. DOI: 10.1634/theoncologist.9-6-687. View

17.

Ozyuvaci E, Altan A, Demir C . [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer]. Agri. 2005; 17(1):49-53. View

18.

Cook R, Major P . Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst. 2001; 93(7):534-8. DOI: 10.1093/jnci/93.7.534. View

19.

Coleman R . Bisphosphonates: clinical experience. Oncologist. 2004; 9 Suppl 4:14-27. DOI: 10.1634/theoncologist.9-90004-14. View

20.

Hoskin P . The RIB trial. Clin Oncol (R Coll Radiol). 2004; 16(7):445-6. DOI: 10.1016/j.clon.2004.07.005. View